Molecular analysis of exhaled breath is a new frontier in medical testing with an enormous potential for monitoring respiratory disease.Breath tests are non-invasive and require minimal patient effort. This makes them applicable in a wide range of settings varying from theintensive care unit (ICU) to home. Respiratory infections are the primary cause of death in ICU. More than half of the patients in ICUsworldwide suffer from infections, which lengthen their hospital stays and increase their mortality rate. Timely detection and treatment isimportant and monitoring infection via breath analysis will have a major impact on healthcare. Electronic nose sensor technology is beingdeveloped but there is a need for clinical validation. Also it is not always clear to which specific compounds these sensors are sensitive. Inthis proposal the focus is on developing a sensor technique, where measurements are obtained and processed at the bedside. Thissolution will be dedicated to the detection of infection from breath. A synergistic approach is proposed between sensor technologydevelopment, clinical validation and complex data interpretation. Knowledge will be exchanged between an industrial partner (Philips, NL)strongly involved in the healthcare and well-being markets, two academic partners (University of Manchester, UK, Academic MedicalCentre, NL) that have an impressive track record in breath analysis research in a clinical environment and a research institution (University of Twente, NL) that has promising potential on bedside gas sensor technology that can be tailored to compounds of interest. The inter-sectorialknowledge transfers as defined in this proposal are key to the success of this ambitious goal. The project consists of 6 highly multidisciplinarywork packages, which involve sensor development, clinical measurements and validation studies and the development ofcomplex data analysis tools.